










	Omicron XBB.1.5 vaccines – PREFERRED			Original/Omicron bivalent vaccines			Original (ancestral) vaccines		
	Pfizer (COMIRNATY) Omicron XBB.1.5 10 mcg/0.3 mL suspension for injection single-dose vial 	Pfizer (COMIRNATY) Omicron XBB.1.5 30 mcg/0.3 mL suspension for injection multi-dose vial 	Moderna (SPIKEVAX) Omicron XBB.1.5 50 mcg/0.5 mL suspension for injection pre-filled syringe 	Moderna (SPIKEVAX) Bivalent BA.4-5 25/25 mcg/0.5 mL suspension for injection pre-filled syringe 	Pfizer (COMIRNATY) Bivalent BA.4-5 15/15 mcg/0.3 mL suspension for injection multi-dose vial 	Pfizer (COMIRNATY) Bivalent BA.1 15/15 mcg/0.3 mL suspension for injection multi-dose vial 	Pfizer (COMIRNATY) 3 mcg/0.2 mL concentrated suspension for injection multi-dose vial 	Pfizer (COMIRNATY) 10 mcg/0.2 mL concentrated suspension for injection multi-dose vial 	Novavax (NUVAXOVID) 5 mcg/0.5 mL adjuvanted suspension for injection multi-dose vial 
CVAS naming convention	Pfizer (XBB.1.5) 5-11 years (Light Blue)	Pfizer (XBB.1.5) 12 years+ (Grey)	Moderna (XBB.1.5) 12 years+ (PFS)	Moderna Bivalent (BA.4-5) 12 years+ (PFS)	Pfizer Bivalent (BA.4-5) 12 years+ (Grey)	Pfizer Bivalent (BA.1) 18 years+ (Grey)	Pfizer 6 months-4 years (Maroon)	Pfizer 5-11 years (Orange)	Novavax
Vaccine type	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	mRNA (nucleic acid)	Protein-based
Approved age	5 to 11 years	12 years and older	12 years and older	12 years and older	12 years and older	18 years and older	6 months to 4 years ¹	5 to 11 years	12 years and older
Dose volume	0.3 mL	0.3 mL	0.5 mL	0.5 mL	0.3 mL	0.3 mL	0.2 mL	0.2 mL	0.5 mL
Doses per vial	1	6	1	1	6	6	10	10	10
Dilution required	No	No	No	No	No	No	Yes (2.2 mL)	Yes (1.3 mL)	No
Recommended primary course interval ²	8 weeks	8 weeks	8 weeks	8 weeks	8 weeks	8 weeks	8 weeks (second dose) and 8 weeks (third dose)	8 weeks	8 weeks
Minimum primary course interval ³	3 weeks	3 weeks	4 weeks	4 weeks	3 weeks	3 weeks	3 weeks (second dose) and 8 weeks (third dose)	3 weeks	3 weeks
Third primary dose ^{2,4}	Yes	Yes	Yes	Yes	Yes	Yes	Yes ⁵	Yes	Yes ⁶
Additional dose interval(s) for eligible cohorts ^{2,7}	6 months or more following last COVID-19 vaccine dose	6 months or more following last COVID-19 vaccine dose	6 months or more following last COVID-19 vaccine dose	6 months or more following last COVID-19 vaccine dose	6 months or more following last COVID-19 vaccine dose	6 months or more following last COVID-19 vaccine dose	NA	6 months or more following last COVID-19 vaccine dose	6 months or more following last COVID-19 vaccine dose
ULT freezer storage time ⁸	24 months (shelf life) at -90°C to -60°C	24 months (shelf life) at -90°C to -60°C	DO NOT STORE below -50°C	DO NOT STORE below -50°C	24 months (shelf life) at -90°C to -60°C	24 months (shelf life) at -90°C to -60°C	24 months (shelf life) at -90°C to -60°C	24 months (shelf life) at -90°C to -60°C	DO NOT STORE
Freezer storage time (unopened) ⁸	DO NOT STORE at -25°C to -15°C	DO NOT STORE at -25°C to -15°C	9 months (shelf life) at -50°C to -15°C	9 months (shelf life) at -50°C to -15°C	DO NOT STORE at -25°C to -15°C	DO NOT STORE at -25°C to -15°C	DO NOT STORE at -25°C to -15°C	DO NOT STORE at -25°C to -15°C	DO NOT STORE
Refrigeration storage time (unopened) ⁸	70 days (+2°C to +8°C) within the 24-month shelf life	70 days (+2°C to +8°C) within the 24-month shelf life	30 days (+2°C to +8°C) within the 9-month shelf life	30 days (+2°C to +8°C) within the 9-month shelf life	70 days (+2°C to +8°C) within the 24-month shelf life	70 days (+2°C to +8°C) within the 24-month shelf life	70 days (+2°C to +8°C) within the 24-month shelf life	70 days (+2°C to +8°C) within the 24-month shelf life	9 months (+2°C to +8°C)
Room temperature storage time (unopened) ⁸	24 hours pre- and post- initial puncture (up to 30°C)	24 hours pre- and post- initial puncture (up to +30°C)	24 hours (up to +25°C)	24 hours (up to +25°C)	24 hours pre- and post- initial puncture (up to +30°C)	24 hours pre- and post- initial puncture (up to +30°C)	24 hours, pre- and post- dilution (up to +30°C)	24 hours, pre- and post- dilution (up to +30°C)	12 hours (up to +25°C)
Storing opened vials	6 hours (up to +30°C)	6 hours (up to +30°C)	NA	NA	6 hours (up to +30°C)	6 hours (up to +30°C)	6 hours (up to +30°C)	6 hours (up to +30°C)	6 hours (up to +25°C)
Storing pre-drawn doses	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	NA	NA	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	1 hour (up to +30°C) or 6 hours (+2°C to +8°C)	Storing pre-drawn doses not preferred ⁹
Transport limitations	80 hours thawed	80 hours thawed	Nil	Nil	80 hours thawed	80 hours thawed	80 hours thawed	80 hours thawed	Nil

Notes:

- COVID-19 vaccination is recommended for children aged 6 months to <5 years with severe immunocompromise, disability, and those who have complex and/or multiple health conditions which increase the risk of severe COVID-19.
- All currently available COVID-19 vaccines are anticipated to provide benefit to eligible people, however the monovalent Omicron XBB.1.5 vaccines are preferred over other vaccines for use in children aged 5 years or older and adults who are currently recommended primary or additional doses of COVID-19 vaccine according to the [Australian Immunisation Handbook](#). For ages in which a monovalent XBB.1.5-containing vaccine is not approved (children aged 6 months to 4 years), Pfizer (COMIRNATY) 6 months-4 years (maroon cap) should be used.
- Dosing intervals can be shortened in specific circumstances for higher risk groups (such as older people or those with medical risk factors for severe illness), or before international travel. The benefits of earlier protection should be weighed against the benefits of the longer dose interval, such as a slightly lower risk of adverse events and a longer duration of protection.
- A third primary dose of COVID-19 vaccine is recommended for all people aged 6 months or older with severe immunocompromise, 2 months after a 2-dose primary course, see [Australian Immunisation Handbook](#).
- Children with severe immunocompromise who receive the 3-dose primary schedule of the Pfizer (COMIRNATY) 6 months to 4 years (maroon cap) vaccine do not require a fourth primary dose.
- There is limited data on the immunogenicity or efficacy of Novavax (NUVAXOVID) in people with immunocompromise, see [ATAGI recommendations](#).
- On 1 September 2023, updated guidance was provided on who should consider receiving an additional dose of a COVID-19 vaccine, see [ATAGI Update on the COVID-19 Vaccination](#).
- If vaccines are stored or handled outside the conditions listed, complete the [Cold Chain Breach \(CCB\) reporting form](#) and email it to the Vaccine Operations Centre (VOC) COVID19VaccineOperationsCentre@health.gov.au.
- If pre-drawn doses are used, where possible, pre-drawn doses in syringes should be used within 1 hour if kept at room temperature, and within 6 hours if kept at +2°C to +8°C. This is to minimise the risk of infection.